EGFR and non-small cell lung carcinoma: Studies suggest (115) that in EGFR wild-type NSCLC patients, conventional EGFR-TKI treatments are ineffective, but using EZH2 inhibitors (such as GSK343 or DZNep) sensitizes lung adenocarcinoma cells to gefitinib (110).